Login / Signup

Electronic monitoring of potential adverse drug events related to lopinavir/ritonavir and hydroxychloroquine during the first wave of COVID-19.

Christian SkalafourisCaroline SamerJerome StirnemannOlivier GrosgurinFrançois EggimannDamien GrauserJean-Luc RenyPascal BonnabryBertrand Guignard
Published in: European journal of hospital pharmacy : science and practice (2021)
During Switzerland's first wave of COVID-19, clinical pharmacy activities during medical rounds in Geneva University Hospitals were replaced by targeted remote interventions. We describe using the electronic PharmaCheck system to screen high-risk situations of adverse drug events (ADEs), particularly targeting prescriptions of lopinavir/ritonavir (LPVr) and hydroxychloroquine (HCQ) in the presence of contraindications or prescriptions outside institutional guidelines. Of 416 patients receiving LPVr and/or HCQ, 182 alerts were triggered for 164 (39.4%) patients. The main associated risk factors of ADEs were drug-drug interactions, QTc interval prolongation, electrolyte disorder and inadequate LPVr dosage. Therapeutic optimisation recommended by a pharmacist or proposals for additional monitoring were accepted in 80% (n=36) of cases. Combined with pharmacist contextualisation to the clinical context, PharmaCheck made it possible to successfully adapt clinical pharmacist activities by switching from a global to a targeted analysis mode in an emergency context.
Keyphrases
  • adverse drug
  • coronavirus disease
  • sars cov
  • healthcare
  • emergency department
  • drug induced
  • cancer therapy
  • newly diagnosed
  • end stage renal disease
  • ejection fraction
  • physical activity
  • single cell
  • data analysis